上海醫藥(601607.SH):控股股東增持完畢 累計增持5684.08萬股H股
格隆匯8月17日丨上海醫藥(601607.SH)公佈,近日,公司收到控股股東上實集團的通知,截至2020年8月15日香港聯合交易所有限公司收市,上實集團增持公司H股股份計劃已經實施完畢。
本次增持期間內,上實集團通過上實國際增持了公司H股股份共計5684.08萬股,約佔公司已發行H股股份總數(即9.19億股)的6.185%和已發行股份總數(即28.42億股)的2.000%。本次增持計劃完成後,上實集團持有及控制公司股份10.12億股,約佔公司已發行股份總數的35.606%;其中持有及控制H股股份7312.52萬股,約佔公司已發行H股股份總數的7.956%和已發行股份總數的2.573%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.